fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

RSV vaccines effective, but more people need to get them

Written by | 31 Oct 2024

Since their introduction last year, researchers have been monitoring the real-world impact of the new respiratory syncytial virus (RSV) vaccines. In a recent commentary in The Lancet, Angela Branche, MD,… read more.

Positive data for Arexvy, respiratory syncytial virus vaccine, indicating protection over three RSV seasons – GSK

Written by | 12 Oct 2024

GSK plc announced new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating the efficacy of a single dose of Arexvy (respiratory syncytial virus vaccine,… read more.

Top-line results of Abrysvo vaccine for RSV in immunocompromised adults – Pfizer

Written by | 15 Aug 2024

Pfizer Inc. announced positive top-line safety and immunogenicity results from sub-study B of the ongoing pivotal Phase III clinical trial ( NCT05842967 ) MONeT (RSV I Mmunizati ONStudy… read more.

Respiratory syncytial virus (RSV) vaccine in late pregnancy not linked to preterm birth

Written by | 20 Jul 2024

Women who receive vaccination against respiratory syncytial virus (RSV) during late pregnancy in order protect a newborn do not have an increased risk of preterm birth, researchers reported… read more.

FDA approves expanded age indication for Arexvy, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk – GSK

Written by | 22 Jun 2024

GSK plc announced that the FDA has approved Arexvy (Respiratory Syncytial Virus (RSV) Vaccine, Adjuvanted) for the prevention of RSV lower respiratory tract disease (LRTD) in adults 50… read more.

Positive top-line results from phase III study of Abrysvo in adults aged 18 to 59 at increased risk for RSV disease – Pfizer

Written by | 14 Apr 2024

Pfizer Inc. announced positive top-line immunogenicity and safety data from the ongoing pivotal Phase III clinical trial (NCT05842967) MONeT (RSV IMmunizatiON Study for AdulTs at Higher Risk of… read more.

MHLW (Japan) approves Beyfortus (nirsevimab) in Japan for the prevention of RSV disease in infants – AstraZeneca

Written by | 2 Apr 2024

AstraZeneca and Sanofi’s Beyfortus (nirsevimab), a long-acting monoclonal antibody, has been approved in Japan for the prophylaxis of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus… read more.

Only 9 percent of older Americans were vaccinated against RSV before the disease hit this fall and winter

Written by | 10 Mar 2024

A new study from the Texas A&M University School of Public Health found that only 9 percent of older Americans had been vaccinated against respiratory syncytial virus (RSV) prior to this fall and winter,… read more.

Arexvy is accepted under Priority Review in US for the prevention of RSV disease in adults aged 50-59 at increased risk – GSK

Written by | 14 Feb 2024

GSK plc announced that the FDA has accepted under priority review an application to extend the indication of GSK’s adjuvanted respiratory syncytial virus (RSV) vaccine to adults aged… read more.

First RSV vaccine to protect infants and older adults

Written by | 7 Sep 2023

EU medicines regulators have approved a vaccine to protect against disease caused by the respiratory syncytial virus (RSV). Abrysvo is the first RSV vaccine indicated for passive immunisation… read more.

EU approves Abrysvo for respiratory syncytial virus – Pfizer

Written by | 3 Sep 2023

Pfizer announced that the European Commission (EC) has granted marketing authorization for Abrysvo, the company’s bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine, to help protect both… read more.

US CDC recommends Beyfortus for prevention of respiratory syncytial virus – Sanofi /AstraZeneca

Written by | 14 Aug 2023

The U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted unanimously 10 to 0 to recommend routine use of Sanofi and AstraZeneca’s… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.